case_images: PMC11235267_01
case_images: The percentage of CD3+ CAR+ T cells in total leucocytes, as analyzed by flow cytometry.
case_images: frtra-02-1238494-g001.jpg
case_images: PMC11235267_01_frtra-02-1238494-g001.jpg
case_images: F1
case_images: On day +10, the circulating CAR-T cells were first checked, reaching a peak of 88% of total lymphocytes on day +14 (good expander) and then decreasing to 8% at day +60 (Figure 1).
case_images: Computed tomography of the chest (axial image).
case_images: frtra-02-1238494-g002.jpg
case_images: PMC11235267_01_frtra-02-1238494-g002.jpg
case_images: F2
case_images: On day +28, a CT scan (Figure 2) showed a worsening of pulmonary infection and the patient required high-flow oxygen therapy.
case_images: Cycle threshold (Ct) values for the E, N, and RdRP/S genes at different time intervals, before and after CAR-T therapy, to determine dynamics of the SARS-CoV-2 viral load. Each dot represents a different time point.
case_images: frtra-02-1238494-g003.jpg
case_images: PMC11235267_01_frtra-02-1238494-g003.jpg
case_images: F3
case_images: Figure 3 shows the cycle-threshold (Ct) evolution for the different genes (gene E, N RdRp, and S) over the time span between lymphodepletion and after the CAR-T cells.
case_images: The patient's timeline. Inside the blue arrow, the main lines of therapy with the corresponding dates are reported. The second red line shows samples of SARS-CoV-2 PCR nasal swabs. Then, in the violet box, the infectious complications during CAR-T cell hospitalization are reported.
case_images: frtra-02-1238494-g004.jpg
case_images: PMC11235267_01_frtra-02-1238494-g004.jpg
case_images: F4
case_images: At day +120, he is well, still in complete remission, and COVID free (Figure 4).